Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis

Neurology

Volumn 70, Issue 14, 2008, Pages 1218-1220

  Aberg L ^a,e   Talling, M ^a   Harkonen T ^a   Lonnqvist T ^a   Knip, M ^a,b   Alen, R ^c   Rantala, H ^d   Tyynela J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF OULU   (Finland)

^e NONE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; PREDNISOLONE;

ADOLESCENT; ADULT; AGGRESSIVENESS; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INTELLIGENCE QUOTIENT; MALE; MOTOR ACTIVITY; NEURONAL CEROID LIPOFUSCINOSIS; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RECURRENT INFECTION; SIDE EFFECT; UNIFIED PARKINSON DISEASE RATING SCALE; WESTERN BLOTTING; WILCOXON SIGNED RANKS TEST;

EID: 41649087313     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000307753.88839.29     Document Type: Article

References (7)

1. Hofman I, Kohlschütter A, Santavuori P, et al. CLN3: Juvenile NCL. In: The Neuronal Ceroid Lipofuscinoses (Batten Disease). IOS Press, 1999.
2. Chattopadhyay S, Ito M, Cooper J, et al. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum Molec Genet 2002;11:1421-1431.
3. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn, Marsden CD, Goldstein M, Calne DB, eds. Recent Development in Parkinson's Disease. Vol II. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.
4. Lamminranta S, Åberg L, Autti T, et al. Neuropsychological test battery in the follow-up of patients with juvenile neuronal ceroid lipofuscinosis. J Intellect Dis Res 2001;45:8-17.
5. Sorva R, Perheentupa J, Tolppanen EM. New format of a growth chart. Acta Paediatr Scand 1984;73:527-529.
6. Kinali M, Mercuri E, Main M, et al. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord 2002;12:169-174.
7. Lim MJ, Noreen A, Benedict JW, et al. IgG entry and deposition are components of the neuroimmune response in Batten disease. Neurobiol Dis 2007;25:239-251.